No Data
Neurocrine Biosciences Publishes Positive Data From Movement Disorder Study
Neurocrine Announces Publication Of Post-Hoc Analysis From Two 48-Week Studies, KINECT 3 Extension And KINECT 4, Demonstrating Long-term Safety Profile And Robust Efficacy Of INGREZZA Capsules In Adults With TD In The Journal Of Clinical Psychiatry
Express News | Evercore ISI Group Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $185
TD Cowen Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
Stifel Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $166
H.C. Wainwright Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $168